Literature DB >> 28585099

Recent advances in targeting DNA-repair pathways for the treatment of ovarian cancer: introduction.

Hiroshi Kobayashi1.   

Abstract

Entities:  

Year:  2017        PMID： 28585099     DOI： 10.1007/s10147-017-1144-8

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  13 in total

1.  Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Authors:  David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 2.  BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.

Authors:  P L Welcsh; M C King
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

3.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 4.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

5.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

Review 6.  PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.

Authors:  J Sehouli; E I Braicu; R Chekerov
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

Review 7.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Authors:  Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charlie Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

Review 9.  The role of double-strand break repair - insights from human genetics.

Authors:  Mark O'Driscoll; Penny A Jeggo
Journal:  Nat Rev Genet       Date:  2006-01       Impact factor: 53.242

Review 10.  Chromatin modifications and DNA repair: beyond double-strand breaks.

Authors:  Nealia C M House; Melissa R Koch; Catherine H Freudenreich
Journal:  Front Genet       Date:  2014-09-05       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.